NCT05734560View on ClinicalTrials.gov

D2C7-IT and 2141-V11 in Newly Diagnosed GBM Patients

PHASE1/PHASE2RecruitingINTERVENTIONAL
Enrollment

50

Participants

Timeline

Start Date

September 6, 2023

Primary Completion Date

October 31, 2026

Study Completion Date

October 31, 2028

Conditions
Newly Diagnosed MGMT Unmethylated Glioblastoma
Interventions
DRUG

D2C7-IT

D2C7-IT will be dosed at 166,075 ng in 36 mL.

DRUG

2141-V11

2141-V11 will be dosed at 3 mg in 3.5 mL for CED administration. 2141-V11 in the cervical perilymphatic subcutaneous area will be dosed at 2 mg.

Trial Locations (1)

27710

RECRUITING

Duke University Medical Center, Durham

All Listed Sponsors
collaborator

Rockefeller University

OTHER

lead

Darell Bigner

OTHER